Rapid Atrial Pacing After TAVI to Predict Pacemaker Implantation
Key facts
- Where
- Brussels, BelgiumSee the site
Where in Belgium
- CHU Saint-PierreBrussels, BelgiumContact: Quentin de Hemptinne, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- National and Kapodistrian University of Athens
- Trial code
- NCT06189976
- Record updated
- 12 December 2024
- Original description
Despite Transcatheter aortic valve implantation (TAVI) evolution regarding techniques, equipment and experience, the need for permanent pacemaker implantation (PPI) post-TAVI remains an important drawback. The electrophysiology testing to stratify the risk or necessity of PPI post-TAVI is endorsed by the up-to-date guidelines and consensus documents and it is a valuable cut-off based method. Part of the answer is maybe hidden in the easy and applicable testing of the atrioventricular conduction system through rapid atrial pacing (RAP) with a common temporary pacemaker lead. This trial is designed to investigate the role and value of RAP after TAVI as a predictor of the necessity of new PPI.Read full original descriptionShow less
Rapid Atrial Pacing After TAVI as a Predictor of Permanent Pacemaker Implantation
Despite Transcatheter aortic valve implantation (TAVI) evolution regarding techniques, equipment and experience, the need for permanent pacemaker implantation (PPI) post-TAVI remains an important drawback. The electrophysiology testing to stratify the risk or necessity of PPI post-TAVI is endorsed by the up-to-date guidelines and consensus documents and it is a valuable cut-off based method. Part of the answer is maybe hidden in the easy and applicable testing of the atrioventricular conduction system through rapid atrial pacing (RAP) with a common temporary pacemaker lead. This trial is designed to investigate the role and value of RAP after TAVI as a predictor of the necessity of new PPI.
Inclusion: Adults ≥18 years old; Patient understands the purpose, the potential risks as well as benefits of the trial and is willing to participate in all parts of the follow-up; Patient has given written consent to participate in the trial; Patients undergoing TAVI as a treatment of severe aortic stenosis (AS); Patient in sinus rhythm; Patients planned for TAVI with utilization of temporary pacemaker electrode placement.
Exclusion: Ongoing infection, including active endocarditis; Implanted permanent pacemaker and/or implantable cardioverter/defibrillator; Patients developing persistent second or third degree atrioventricular block (AV) after TAVI; Underlying rhythm other than sinus based on the surface ECG leads monitoring after TAVI; Patients with second or third degree AV block identifyied on the screening pre-TAVI ECG; Enrolment in another study that competes or interferes with this study; Subject will not be able to comply with the follow-up requirements according to investigators' opinion; Pregnant or breast-feeding females or females who intend to become pregnant during the time of the study.